BioVie
BIVI

$0.47

6.19%

Market Cap: 28.7M

About: BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 18

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

53% more capital invested

Capital invested by funds: $2.32M [Q4 2023] → $3.55M (+$1.23M) [Q1 2024]

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

7.34% more ownership

Funds ownership: 4.87% [Q4 2023] → 12.21% (+7.34%) [Q1 2024]

7% less funds holding

Funds holding: 54 [Q4 2023] → 50 (-4) [Q1 2024]

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

80% less call options, than puts

Call options by funds: $47K | Put options by funds: $231K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$3

538%

upside

Avg. target

$3

538%

upside

High target

$3

538%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

ThinkEquity

Ashok Kumar

538%upside

$3

Buy

Initiated

1 Jul 2024

See Analyst Rankings

Financial journalist opinion

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m.

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson's disease

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to invite investors to a webinar on June 26, 2024, at 4:15 p.m. ET.

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Proactive Investors

BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment

BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms associated with long COVID.

BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Proactive Investors

BioVie presents new data showing lead drug asset may promote healthier aging

BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston from April 23 to 25. Additionally, the company said that bezisterim has been approved as the generic name for NE3107 by the United States Adopted Names Council and World Health Organization International Nonproprietary Names expert committee.

BioVie presents new data showing lead drug asset may promote healthier aging

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

See News Rankings